Loading...
Loading...
Chat is set up on each filing report page.
Ask about this filing, its industry, or sector trends.
AI responses are generated from filing and peer context and may contain errors.
ITEM 1A. RISK FACTORS
There have been no material changes from the risk factors previously disclosed in Part I, Item 1A of the Companys Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on April 22, 2024 (the Form 10-K), and in our Quarterly Report on Form 10-Q for the quarter ended Mareach 31, 2024 filed with the SEC on June 26, 2024 (Form 10-Q), in each ccase under the heading Risk Factors, except for the risks inherent in the assets and operations of Scienture that pertain to the Company after the completion of the merger transaction completed in July 2024 and as set forth below, and investors should review the risks provided in the Form 10-K, Form 10-Q and below, prior to making an investment in the Company. The business, financial condition and operating results of the Company can be affected by a number of factors, whether currently known or unknown, including but not limited to those described in the Form 10-K and the Form 10-Q and below, any one or more of which could, directly or indirectly, cause the Companys actual financial condition and operating results to vary materially from past, or from anticipated future, financial condition and operating results. Any of these factors, in whole or in part, could materially and adversely affect the Companys business, financial condition, operating results and stock price.
The Companys stockholders may not realize a benefit from the merger commensurate with the ownership dilution they will experience in connection with the merger.
The Company and Scienture completed a merger transaction on July 25, 2024 as generally described in this report (and other reports and filings we have filed with the SEC), and, if the combined company is unable to realize the full strategic and financial benefits currently anticipated from the merger, the Companys stockholders will have experienced dilution of their ownership interests in the Company without receiving any commensurate benefit, or only receiving part of the commensurate benefit to the extent the combined company is able to realize only part of the strategic and financial benefits currently anticipated from the merger.
3 |
|